Company news

Telo Genomics Corp. (TSXV:TELO) news

Telo Genomics Corp. news releases on 6ix. Latest, Sep 29, 2026: Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD…

Telo Genomics Corp. (TSXV:TELO) news

Press releases & updates

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Telo Genomics Grants Stock Options

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Telo Genomics Announces Termination of Investor Relations Agreement

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Telo Genomics Closes First Tranche of Convertible Debentures Financing

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000

Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Small Cap Growth Virtual Investor Conference Agenda Announced for December 9th

Telo Genomics Corp to Present at the Small Cap Growth&#xA0;Virtual Investor Conference December 9th

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th

Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025

American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition

Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update

Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting

Telo Geonomics Announces Engagement of Investor Relations Service Provider

OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing

Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference

OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th

International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting

Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President

Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)

European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress

Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025

Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors

Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors

Telo Genomics Announces Expanded Partnership with Trusted Health Advisors

Telo Genomics Closes Oversubscribed $2.5 Million Private Placement

Telo Genomics Announces Private Placement for up to $2 Million

Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)

Telo Genomics Expands its Strategic Collaboration with Mayo Clinic

Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test

Telo Genomics Assessing MRD Status in TELO-DMRD Study

Telo Genomics Receives CLIA Certification

Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024

Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology

Telo Genomics and Emery Pharma Announce Collaboration

Telo Genomics Receives Accreditation from College of American Pathologists

Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th